Abstract 5139
Background
The prognostic value of the inflammatory indexes (eg. neutrophil-to-lymphocyte ratio, NLR; and systemic immune-inflammation index, SII) was demonstrated among patients with epithelial ovarian cancer (EOC). This study aimed to evaluate their predictive value in terms of platinum-free interval (PFI) as regard to bevacizumab treatment received.
Methods
A total of 375 EOC patients were retrospectively analyzed, 301 treated with chemotherapy alone and 74 with bevacizumab, with the decision to include this drug in the chemotherapy regimen left to the discretion of the treating physician. The correlation between NLR (defined as the ratio of neutrophil to lymphocyte count) and SII, calculated as (platelet count × neutrophil count)/lymphocyte count, and PFI were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Cutoff values were determined using Receiver Operating Characteristic (ROC) analysis.
Results
In univariate analysis, patients with high NLR (≥3) and SII (≥730) had a significantly shorter PFI at 6 and 12 months in overall cohort. In multivariate analysis, only NLR was an independent predictive factor for PFI at 6 months (OR = 2.52, 95% CI 1.30–4.87, p = 0.006) and at 12 months (OR = 2.05, 95% CI 1.05–4.01, p = 0.036) in the overall population and in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004; HR = 2.27, 95% CI 1.10–4.70, p = 0.027, respectively). Inflammatory indexes were not predictive for PFI in the bevacizumab group (Table).Table: 1020P
PFI at 6 months | PFI at 12 months | |||||||
---|---|---|---|---|---|---|---|---|
N. pts | N. pts | OR (95% CI) | p | N. pts | N. pts | OR (95% CI) | p | |
NLR | ||||||||
<3 | 74 | 139 | 1.00 | 113 | 98 | 1.00 | ||
≥3 | 80 | 68 | 2.52 (1.30-4.87) | 0.006 | 106 | 37 | 2.05 (1.05-4.01) | 0.036 |
SII | ||||||||
<730 | 52 | 99 | 1.00 | 76 | 73 | 1.00 | ||
≥730 | 102 | 108 | 0.74 (0.36-1.53) | 0.413 | 143 | 62 | 0.91 (0.45-1.84) | 0.786 |
CT | ||||||||
NLR | ||||||||
<3 | 62 | 115 | 1.00 | 98 | 78 | 1.00 | ||
≥3 | 69 | 48 | 2.77 (1.38-5.56) | 0.004 | 89 | 24 | 2.27 (1.10-4.70) | 0.027 |
SII | ||||||||
<730 | 41 | 80 | 1.00 | 63 | 56 | 1.00 | ||
≥730 | 90 | 83 | 0.76 (0.35-1.67) | 0.498 | 124 | 46 | 0.84 (0.39-1.82) | 0.663 |
CT+B | ||||||||
NLR | ||||||||
<3 | 12 | 24 | 1.00 | 15 | 20 | 1.00 | ||
≥3 | 11 | 20 | 0.47 (0.04-5.15) | 0.538 | 17 | 13 | 0.75 (0.11-5.25) | 0.774 |
SII | ||||||||
<730 | 11 | 19 | 1.00 | 13 | 17 | 1.00 | ||
≥730 | 12 | 25 | 1.65 (0.13-20.56) | 0.696 | 19 | 16 | 1.78 (0.21-15.14) | 0.599 |
Conclusions
The NLR was an independent predictive factor for platinum-sensitivity in patients with EOC treated with chemotherapy. Its predictive role seems to be lost in patients treated with bevacizumab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MITO group.
Funding
MITO group.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3608 - Prognostic impact of Body Mass Index (BMI) on overall survival in patients with metastatic breast cancer
Presenter: Khalil SALEH
Session: Poster Display session 2
Resources:
Abstract
2686 - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: a multicenter study
Presenter: Marion Alhenc Gelas
Session: Poster Display session 2
Resources:
Abstract
1565 - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer
Presenter: Heekyung Ahn
Session: Poster Display session 2
Resources:
Abstract
4498 - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries
Presenter: Thomais Konstantopoulou
Session: Poster Display session 2
Resources:
Abstract
1423 - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study
Presenter: Diana Lüftner
Session: Poster Display session 2
Resources:
Abstract
2284 - Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Presenter: Hee Kyung Kim
Session: Poster Display session 2
Resources:
Abstract
4598 - Administration of chemotherapy for metastatic breast cancer near the end of life: a population registry study
Presenter: Luisa Edman Kessler
Session: Poster Display session 2
Resources:
Abstract
5706 - Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases
Presenter: Ali Bohlok
Session: Poster Display session 2
Resources:
Abstract
1697 - Illness perceptions, quality of life and mood in metastatic breast cancer patients
Presenter: Isabel Domingues
Session: Poster Display session 2
Resources:
Abstract
1935 - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer:An Analysis of 2010–2014 SEER Data
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract